Niagen Bioscience Inc (NAGE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 03-2022 | 12-2021 | 09-2021 | 06-2021 | 03-2021 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -7,740 | -27,128 | -21,803 | -12,947 | -7,381 |
| Depreciation Amortization | 250 | 1,115 | 853 | 568 | 281 |
| Accounts receivable | -1,094 | -2,578 | -2,448 | -3,331 | -1,967 |
| Accounts payable and accrued liabilities | -643 | 978 | 1,359 | 525 | 2,248 |
| Other Working Capital | -1,923 | -5,010 | -3,311 | -4,158 | 243 |
| Other Operating Activity | 3,952 | 8,460 | 6,131 | 6,043 | 1,171 |
| Operating Cash Flow | $-7,198 | $-24,163 | $-19,219 | $-13,300 | $-5,405 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -25 | -409 | -407 | -311 | -46 |
| Investing Cash Flow | $-25 | $-409 | $-407 | $-311 | $-46 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | N/A | 36,235 | 36,105 | 35,764 | 33,504 |
| Other Financing Activity | -3 | -141 | -74 | -72 | -59 |
| Financing Cash Flow | $-3 | $36,094 | $36,031 | $35,692 | $33,445 |
| Beginning Cash Position | 28,219 | 16,697 | 16,697 | 16,697 | 16,697 |
| End Cash Position | 20,993 | 28,219 | 33,102 | 38,778 | 44,691 |
| Net Cash Flow | $-7,226 | $11,522 | $16,405 | $22,081 | $27,994 |
| Free Cash Flow | |||||
| Operating Cash Flow | -7,198 | -24,163 | -19,219 | -13,300 | -5,405 |
| Capital Expenditure | -25 | -409 | -407 | -311 | -46 |
| Free Cash Flow | -7,223 | -24,572 | -19,626 | -13,611 | -5,451 |